An interventional study of Saline 0.06 ml/kg and Rocuronium 0.2 mg/kg in Anesthesia and Neuromuscular Blockade, sponsored by Medtronic - MITG. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-05-12.
Sponsored by Medtronic - MITG (part of Medtronic) · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The Bispectral Index (BIS) monitor is used in many operating rooms to provide information to the anesthesiologist about a patient's level of consciousness. The Composite Variability Index (CVI) is a new index that may provide the anesthesiologist with more information about the condition of the patient. The CVI is a measure of the combined variability in BIS (bispectral index) and frontal electromyography (EMG) activity that may be useful in assessing the nociception/anti-nociception balance for patients under general anesthesia.The purpose of this study is to determine if a commonly used anesthetic drug (rocuronium) affects the CVI measurement differently with different doses. Rocuronium is a neuromuscular blocking agent (NMBA) routinely used during surgery. It is expected that the group given the highest dose of rocuronium will have diminished CVI values.
This study will randomize patients to one of four doses of rocuronium: no rocuronium, 0.2, 0.4, and 0.6 milligrams per kilo of body weight; the last dose is the standard amount for adults. It is expected that the group given the highest dose of rocuronium will have diminished CVI values. By including intermediate doses, information about the function of CVI in states of less than full muscle relaxation, or paralysis, will be obtained. This information is critically important for the development of the composite variability index, because during general anesthesia patients are usually maintained in a state of less than full paralysis. If the CVI response to stimulation in the intermediate groups is similar to the group receiving no rocuronium, the monitor may find wide clinical applicability. If the response is similar to the maximal rocuronium group, the index may only be reliable in states with no muscle relaxant, which will greatly limit clinical utility.
Consented subjects randomized to one of four doses of rocuronium will be transported to the operating room and be connected to routine monitors that included a BIS (Covidien), M-Entropy sensor (GE Healthcare) and TOF (train of four) monitor. Following preoxygenation, general anesthesia will be induced with propofol and remifentanil using traditional syringe pumps. The induction doses given and subsequent infusion rates will be determined by utilizing pharmacokinetic (Pk) models (Marsh model for propofol, Minto model for remifentanil). Unconsciousness will be confirmed by performing the usual clinical assessments and by obtaining a BIS value between 40 and 50. Once the subject is unconsciousness, they will be given the assigned dose of rocuronium, after which the study anesthesiologist will perform a laryngoscopy. The anesthesiologist performing the laryngoscopy will not know what dose of rocuronium the subject received. Neuromuscular blockade (NMB) will be monitored by a train-of-four twitch monitor (TOF Watch-SX) at the adductor pollicis muscle (2 HZ, 50mAmp) every 15 seconds.
At three minutes after the rocuronium administration, a standardized 20-second laryngoscopy will be applied. The CVI, entropy, and hemodynamic responses (heart rate, blood pressure measurement each minute) and train-of-four measurements will be monitored for three minutes before and after the laryngoscopy.
Medtronic - MITG is the lead sponsor of 179 studies on the registry; 4 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 17 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Saline 0.06 ml/kg
Drug: Saline 0.06 ml/kg
Rocuronium 0.2 mg/kg
Drug: Rocuronium 0.2 mg/kg
Rocuronium 0.4 mg/kg
Drug: Rocuronium 0.4 mg/kg
Rocuronium 0.6 mg/kg
Drug: Rocuronium 0.6 mg/kg
IV Infusion x1 prior to laryngoscopy
Also known as: Normal Saline
Drug page: Rocuronium
IV Infusion x1 prior to laryngoscopy
Also known as: Rocuronium bromide: Zemuron
Drug page: Rocuronium
IV Infusion x1 prior to laryngoscopy
Also known as: Rocuronium bromide: Zemuron
Drug page: Rocuronium
IV Infusion x1 prior to laryngoscopy
Also known as: Rocuronium bromide: Zemuron
The Mean Difference in CVI Between Pre-laryngoscopy and Post-laryngoscopy for Each of the Four Rocuronium Groups
The difference between the mean CVI in three minutes prior to laryngoscopy and three minutes following laryngoscopy reported as the mean change in CVI and the +/- 95% confidence interval for each group. The Composite Variability Index (CVI) scale is a logistic regression of three measures of processed electroencephalography (EEG) signals. These signals are Bispectral Index (BIS), the variability of electromyelogram (sEMG), and the variability of BIS (sBIS). The scale ranges from 0 to 100 where a lower CVI value represents a lower likelihood of intraoperative somatic responses, and a higher CVI value represents a higher likelihood of intraoperative somatic responses.
Time frame: Six minutes after the dose of rocuronium with laryngoscopy at 3 minutes after the study intervention
The Average CVI During the Maintenance Phase of Anesthesia for the Two Remifentanil Groups
Mean CVI from incision to propofol off reported as the mean CVI +/- 95% confidence interval for the two groups
Time frame: Maintenance Anesthesia
| Milestone | Group 1 | Group 2 | Group 3 | Group 4 |
|---|---|---|---|---|
| Started | 20 | 20 | 20 | 20 |
| Completed | 19 | 19 | 20 | 17 |
| Not completed | 1 | 1 | 0 | 3 |
| Withdrew: Physician decision | 1 | 1 | 0 | 3 |
The difference between the mean CVI in three minutes prior to laryngoscopy and three minutes following laryngoscopy reported as the mean change in CVI and the +/- 95% confidence interval for each group. The Composite Variability Index (CVI) scale is a logistic regression of three measures of processed electroencephalography (EEG) signals. These signals are Bispectral Index (BIS), the variability of electromyelogram (sEMG), and the variability of BIS (sBIS). The scale ranges from 0 to 100 where a lower CVI value represents a lower likelihood of intraoperative somatic responses, and a higher CVI value represents a higher likelihood of intraoperative somatic responses.
| units on a scale | Group 1 | Group 2 | Group 3 | Group 4 |
|---|---|---|---|---|
| The Mean Difference in CVI Between Pre-laryngoscopy and Post-laryngoscopy for Each of the Four Rocuronium Groups | 2.40 (2.15 to 2.64) | 1.39 (0.95 to 1.83) | 0.48 (0.24 to 0.72) | 0.17 (-0.04 to 0.38) |
Mean CVI from incision to propofol off reported as the mean CVI +/- 95% confidence interval for the two groups
| units on a scale | Remifentanil 2ng/ml | Remifentanil 8 ng/ml |
|---|---|---|
| The Average CVI During the Maintenance Phase of Anesthesia for the Two Remifentanil Groups | 1.73 (1.56 to 1.9) | 1.38 (1.31 to 1.45) |
Collected over 1 year. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1 | — | 0/19 (0%) | 0/19 (0%) |
| Group 2 | — | 0/19 (0%) | 0/19 (0%) |
| Group 3 | — | 0/20 (0%) | 0/20 (0%) |
| Group 4 | — | 0/17 (0%) | 0/17 (0%) |
| Age, Continuous(years) | Group 1 | Group 2 | Group 3 | Group 4 | Total |
|---|---|---|---|---|---|
| Mean | 35.9 ± 12.3 | 38.6 ± 14.6 | 39.4 ± 12.7 | 32.9 ± 6.4 | 37.9 ± 11.34 |
| Sex: Female, Male(Participants) | Group 1 | Group 2 | Group 3 | Group 4 | Total |
|---|---|---|---|---|---|
| Female | 9 | 8 | 8 | 9 | 34 |
| Male | 10 | 11 | 12 | 8 | 41 |
Plan to share: No — Data collected was for device algorithm development
No publications or documents are linked to this record.
The record gives a start of Jun 2009, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.
Results were first posted in May 2017, 3 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rocuronium